Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00621244 · OUTCOME

Percentage of Participants With Histone Acetylation Induction in Peripheral Blood in Arm 2 (MWF Every Other Week), Group Y

A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies · Source last updated 2021-01-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentages of participants
Interval / dispersion
Not reported
Time frame
Days 5, 8, 10, 12, 15, End of study (up to 3.5 years)

Analysis population: Full Analysis Set

Groups in this outcome

Arm 2, Group Y (30 mg)

Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF)

Arm 2, Group Y (45 mg)

Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF)

Arm 2, Group Y (60 mg)

Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm 2, Group Y (30 mg)1
Arm 2, Group Y (45 mg)7
Arm 2, Group Y (60 mg)15

Reported measurements

Day 5 (total=1, 4, 6)
Values in Percentages of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Arm 2, Group Y (30 mg)100.0Not reportedNot reportedNot reportedNot reported
Arm 2, Group Y (45 mg)100.0Not reportedNot reportedNot reportedNot reported
Arm 2, Group Y (60 mg)100.0Not reportedNot reportedNot reportedNot reported
Day 8 (total = 1, 4, 6)
Values in Percentages of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Arm 2, Group Y (30 mg)100.0Not reportedNot reportedNot reportedNot reported
Arm 2, Group Y (45 mg)100.0Not reportedNot reportedNot reportedNot reported
Arm 2, Group Y (60 mg)83.3Not reportedNot reportedNot reportedNot reported
Day 10 (total=1, 4, 5)
Values in Percentages of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Arm 2, Group Y (30 mg)NANot reportedNot reportedNot reportedno patients with positive reading (greater than two fold increased when compared to baseline) at this time point in the dose group.
Arm 2, Group Y (45 mg)50.0Not reportedNot reportedNot reportedNot reported
Arm 2, Group Y (60 mg)60.0Not reportedNot reportedNot reportedNot reported
Day 12 (Total=0, 3, 5)
Values in Percentages of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Arm 2, Group Y (30 mg)NANot reportedNot reportedNot reportedNo patients were analyzed for this arm.
Arm 2, Group Y (45 mg)33.3Not reportedNot reportedNot reportedNot reported
Arm 2, Group Y (60 mg)40.0Not reportedNot reportedNot reportedNot reported
Day 15 (Total=1, 3, 5)
Values in Percentages of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Arm 2, Group Y (30 mg)100.0Not reportedNot reportedNot reportedNot reported
Arm 2, Group Y (45 mg)33.3Not reportedNot reportedNot reportedNot reported
Arm 2, Group Y (60 mg)0Not reportedNot reportedNot reportedNot reported
End of Study (Total=0, 2, 0)
Values in Percentages of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Arm 2, Group Y (30 mg)NANot reportedNot reportedNot reportedNo patients were analyzed for this arm.
Arm 2, Group Y (45 mg)50.0Not reportedNot reportedNot reportedNot reported
Arm 2, Group Y (60 mg)NANot reportedNot reportedNot reportedNo patients were analyzed for this arm.
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        100.0
      2. group Id
        OG001
        value
        100.0
      3. group Id
        OG002
        value
        100.0
    title
    Day 5 (total=1, 4, 6)
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        100.0
      2. group Id
        OG001
        value
        100.0
      3. group Id
        OG002
        value
        83.3
    title
    Day 8 (total = 1, 4, 6)
  3. categories
    1. measurements
      1. comment
        no patients with positive reading (greater than two fold increased when compared to baseline) at this time point in the dose group.
        group Id
        OG000
        value
        NA
      2. group Id
        OG001
        value
        50.0
      3. group Id
        OG002
        value
        60.0
    title
    Day 10 (total=1, 4, 5)
  4. categories
    1. measurements
      1. comment
        No patients were analyzed for this arm.
        group Id
        OG000
        value
        NA
      2. group Id
        OG001
        value
        33.3
      3. group Id
        OG002
        value
        40.0
    title
    Day 12 (Total=0, 3, 5)
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        100.0
      2. group Id
        OG001
        value
        33.3
      3. group Id
        OG002
        value
        0
    title
    Day 15 (Total=1, 3, 5)
  6. categories
    1. measurements
      1. comment
        No patients were analyzed for this arm.
        group Id
        OG000
        value
        NA
      2. group Id
        OG001
        value
        50.0
      3. comment
        No patients were analyzed for this arm.
        group Id
        OG002
        value
        NA
    title
    End of Study (Total=0, 2, 0)
denoms
  1. counts
    1. group Id
      OG000
      value
      1
    2. group Id
      OG001
      value
      7
    3. group Id
      OG002
      value
      15
    units
    Participants
groups
  1. description
    Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF)
    id
    OG000
    title
    Arm 2, Group Y (30 mg)
  2. description
    Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF)
    id
    OG001
    title
    Arm 2, Group Y (45 mg)
  3. description
    Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF)
    id
    OG002
    title
    Arm 2, Group Y (60 mg)
param Type
NUMBER
population Description
Full Analysis Set
reporting Status
POSTED
time Frame
Days 5, 8, 10, 12, 15, End of study (up to 3.5 years)
title
Percentage of Participants With Histone Acetylation Induction in Peripheral Blood in Arm 2 (MWF Every Other Week), Group Y
type
SECONDARY
unit Of Measure
Percentages of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice